X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NM-002 (vurolenatide), a proprietary long-acting GLP-1 agonist for short bowel syndrome as well as an anti-GIP monoclonal antibody and plans to conduct a Phase 3 trial with vurolenatide in patients with short bowel syndrome.
Lead Product(s): Vurolenatide
Therapeutic Area: Gastroenterology Product Name: NM-002
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 30, 2023
Details:
NM-136 is a novel humanized monoclonal antibody antagonist targeting glucose-dependent insulinotropic polypeptide (GIP). Pre-clinical data has demonstrated that anti-GIP monoclonal antibodies can effectively produce weight loss in obese mice without affecting food consumption.
Lead Product(s): NM-136
Therapeutic Area: Nutrition and Weight Loss Product Name: NM-136
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2023
Details:
The Company intends to use the net proceeds, to support the clinical development of NM-002 (vurolenatide) for the treatment of short bowel syndrome and to fund the development of the Company's other pipeline programs.
Lead Product(s): Vurolenatide
Therapeutic Area: Gastroenterology Product Name: NM-002
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 15, 2023
Details:
The Company intends to use the net proceeds, to support the clinical development of NM-002 (vurolenatide) for the treatment of short bowel syndrome and to fund the development of the Company's other pipeline programs.
Lead Product(s): Vurolenatide
Therapeutic Area: Gastroenterology Product Name: NM-002
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 14, 2023
Details:
The therapeutic effect of immune checkpoint inhibitors (ICIs), such as antibodies to CTLA-4 and PD-1, might be enhanced by preventing bacterial antigens, toxins, and certain metabolites in the gut from interacting with the host immune system utilizing NM-102.
Lead Product(s): NM-102
Therapeutic Area: Gastroenterology Product Name: NM-102
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Gustave Roussy
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 14, 2022
Details:
NM-136, an anti-GIP humanized mAb, for targeted obesity disorders has demonstrated that the anti-GIP hu-mAb has a robust half-life, excellent humanness score, a high affinity for the GIP receptor.
Lead Product(s): NM-136
Therapeutic Area: Nutrition and Weight Loss Product Name: NM-136
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2022
Details:
Vurolenatide (NM-002) 50 mg every two weeks (Q2W) dosing arm demonstrated a 30% reduction over six weeks in the primary endpoint of the Phase 2 study, mean reduction in total stool output (TSO), compared with a 32% increase for placebo - for a mean relative reduction of 62%.
Lead Product(s): Vurolenatide
Therapeutic Area: Gastroenterology Product Name: NM-002
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2022
Details:
NM-002 (vurolenatide) is long-acting injectable GLP-1 receptor agonist that utilizes XTEN® technology to extend its circulating half-life. GLP-1, referred to "ileal brake", is hormone that slows transit of food and fluid through stomach and upper intestine following meal.
Lead Product(s): Vurolenatide
Therapeutic Area: Gastroenterology Product Name: NM-002
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2022
Details:
This study follows a Phase 2 clinical trial in 342 adult patients with celiac disease who had been on a gluten-free diet for at least 12 months, which concluded that INN-202 (larazotide) 0.5 mg significantly reduced symptoms of celiac disease.
Lead Product(s): Larazotide Acetate
Therapeutic Area: Gastroenterology Product Name: INN-202
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2022
Details:
Vurolenatide, a novel chemical entity and long-acting injectable GLP-1 receptor agonist used to improve gastric motility. Company initiated the largest placebo-controlled Phase 2 trial in treatment of Short Bowel Syndrome.
Lead Product(s): Vurolenatide
Therapeutic Area: Gastroenterology Product Name: NM-002
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
